Several drugs [docetaxel, pemetrexed, erlotinib, gefitinib (outside U.S and in China), and ramucirumab combined with docetaxel] have been approved as single agents or combination for second line therapy for locally advanced or metastatic NSCLC, but with limited efficacy, that is, limited clinical significant improvement or overall survival.